La tunisie Medicale - 2022 ; Vol 100 ( n°08 ) : 652-655
[ 343 times seen ]

Introduction : Children’s Interstitial Lung Diseases (cHILD) are a heterogeneous group of rare respiratory diseases. Their common characteristics are gas exchange abnormalities and diffuse pulmonary infiltrates on chest imaging. This group includes inherited surfactant protein deficiency (ISPD), a little-known etiology in Tunisia.
Case Presentation : A 22-month-old boy was referred to investigate recurrent respiratory infections. He had polypnea, cyanosis, finger clubbing, pectus carinatum, intercostal retraction, and bilateral crackles on pulmonary auscultation. The chest imaging revealed a diffuse ground-glass appearance consistent with cHILD. Lung biopsy was suggestive of ISPD. The infant was mainly treated with intravenous corticosteroids. At the age of nine, he was still dependent on oxygen but had better exercise tolerance.
Conclusion : This case showed that recurrent respiratory infections can hide cHILD which may be related to ISPD, particularly in infants. A better knowledge of this disease was necessary to start specific treatment. Early management would lead to better prognosis.

Key - Words
  1. Cunningham S, Jaffe A, Young LR. Children’s interstitial and diffuse lung disease. Lancet Child Adolesc Health. 2019;3(8):568‑77. doi: 10.1016/S2352-4642(19)30117-8.
  2. Clement A, Nathan N, Epaud R, Fauroux B, Corvol H. Interstitial lung diseases in children. Orphanet J Rare Dis. 2010;5:22. doi: 10.1186/1750-1172-5-22.
  3. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; CARE Group*. The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development. Glob Adv Health Med. 2013 Sep;2(5):38-43. doi: 10.7453/gahmj.2013.008. PMID: 24416692; PMCID: PMC3833570
  4. Kitazawa H, Kure S. Interstitial Lung Disease in Childhood: Clinical and Genetic Aspects. Clin Med Insights Circ Respir Pulm Med. 2015;9(Suppl 1):57-68. doi: 10.4137/CCRPM.S23282
  5. Al Anazi A, Epaud R, Heena H, de Becdelievre A, Miqdad AM, Fanen P. The most frequent ABCA3 nonsense mutation -p.Tyr1515* (Y1515X) causing lethal neonatal respiratory failure in a term neonate. Ann Thorac Med. 2017;12(3):213–215. doi: 10.4103/atm.ATM_386_16
  6. Cole FS, Nogee LM, Hamvas A. Defects in surfactant synthesis: clinical implications. Pediatr Clin North Am. 2006;53(5):911‑27. doi: 10.1016/j. pcl.2006.08.006.
  7. Doan ML, Guillerman RP, Dishop MK, Nogee LM, Langston C, Mallory GB, et al. Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax. 2008;63(4):366-73. doi: 10.1136/ thx.2007.083766.
  8. Flamein F, Riffault L, Muselet-Charlier C, Pernelle J, Feldmann D, Jonard L, et al. Molecular and cellular characteristics of ABCA3 mutations associated with diffuse parenchymal lung diseases in children. Hum Mol Genet. 2012;21(4):765‑75. doi: 10.1093/hmg/ddr508.
  9. Thouvenin G, Abou Taam R, Flamein F, Guillot L, Le Bourgeois M, Reix P, et al. Characteristics of disorders associated with genetic mutations of surfactant protein C. Arch Dis Child. 2010;95(6):449‑54. doi: 10.1136/adc.2009.171553.
  10. Nogee LM, Garnier G, Dietz HC, Singer L, Murphy AM, deMello DE, et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest. 1994;93(4):1860‑3. doi: 10.1172/JCI117173.
  11. Mechri M, Epaud R, Emond S, Coulomb A, Jaubert F, Tarrant A, et al. Surfactant protein C gene (SFTPC) mutation-associated lung disease: high-resolution computed tomography (HRCT) findings and its relation to histological analysis. Pediatr Pulmonol. 2010;45(10):1021‑9. doi: 10.1002/ppul.21289.
  12. Kröner C, Wittmann T, Reu S, Teusch V, Klemme M, Rauch D, et al. Lung disease caused by ABCA3 mutations. Thorax. 2017;72(3):213- 20. doi: 10.1136/thoraxjnl-2016-208649.
  13. Gupta A, Zheng SL. Genetic disorders of surfactant protein dysfunction: when to consider and how to investigate. Arch Dis Child. 2017;102(1):84‑90. doi: 10.1136/archdischild-2012-303143.
  14. Vece TJ, Young LR. Update on Diffuse Lung Disease in Children. Chest. 2016;149(3):836-45. doi: 10.1378/chest.15-1986.
  15. Bush A, Cunningham S, de Blic J, Barbato A, Clement A, Epaud R, et al. European protocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax. 2015;70(11):1078‑84. doi: 10.1136/thoraxjnl-2015-207349.
  16. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais J-P. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax. 2006;61(10):895‑902. doi: 10.1136/thx.2005.057950.
  17. Raghu G, Craig Johnson W, Lockhart D, Mageto Y. Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone. Am J Respir Crit Care Med. 1999;159(4):1061-9. doi: 10.1164/ajrccm.159.4.9805017.
  18. Richeldi L, du Bois RM, Raghu G, Azuma A, BrownKK, Costabel U, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med 2014;370:2071-82. doi: 10.1056/NEJMoa1402584.
E-mail :
Password :
Remember Me Forgot password? Sign UP
Keywords most used
Tunisia treatment diagnosis Child surgery prognosis Children epidemiology Risk factors Crohn’s disease prevalence Breast cancer obesity screening Cancer
Sign up to receive our newsletter
E-mail :
Stay in Touch
Join Us! !